Validations: Biologics, ATMP & Viral Safety Validation

Lifecycle of COI/COC Records: Retention & Retrieval

Lifecycle of COI/COC Records: Retention & Retrieval The lifecycle management of Chain-of-Identity (COI) and Chain-of-Custody (COC) records is critical in the pharmaceutical industry, particularly in the development and validation of biologics and Advanced Therapy Medicinal Products (ATMPs). A robust understanding of regulatory requirements, best practices for retention, and retrieval processes is essential for professionals engaged in quality assurance, regulatory affairs,…

Continue Reading Lifecycle of COI/COC Records: Retention & Retrieval

Mock Recalls/Simulations Focused on COI/COC

Mock Recalls/Simulations Focused on COI/COC Mock Recalls/Simulations Focused on Chain-of-Identity and Chain-of-Custody In the highly regulated field of biologics and advanced therapy medicinal products (ATMPs), ensuring the integrity of the chain-of-identity (COI) and chain-of-custody (COC) is paramount. This article presents a step-by-step guide aimed at pharmaceutical professionals involved in validation processes, focusing on mock recalls and simulations specifically tailored for…

Continue Reading Mock Recalls/Simulations Focused on COI/COC

Training for COI/COC: Roles and Competency

Training for COI/COC: Roles and Competency Understanding Chain-of-Identity and Chain-of-Custody in Biologics Chain-of-Identity (COI) and Chain-of-Custody (COC) are critical components in biologics manufacturing, particularly for Advanced Therapy Medicinal Products (ATMPs). These concepts ensure traceability, accountability, and safety throughout the lifecycle of a product. Effective training in COI and COC principles equips pharmaceutical professionals with the necessary knowledge to manage and…

Continue Reading Training for COI/COC: Roles and Competency

COI/COC Deviations: CAPA and Effectiveness

COI/COC Deviations: CAPA and Effectiveness COI/COC Deviations: CAPA and Effectiveness This tutorial provides a comprehensive step-by-step guide for pharmaceutical professionals focused on Chain-of-Identity (COI) and Chain-of-Custody (COC) deviations, highlighting the importance of Corrective and Preventive Actions (CAPA) and effectiveness in the context of viral clearance validation, particularly in biologics, Advanced Therapy Medicinal Products (ATMP), and their associated complex critical quality…

Continue Reading COI/COC Deviations: CAPA and Effectiveness

COI/COC in Closed vs Open Steps

COI/COC in Closed vs Open Steps: A Comprehensive Guide for Pharmaceutical Validation In the realm of pharmaceutical and biologics development, maintaining stringent quality assurance protocols is paramount. This holds especially true for Chain-of-Identity (COI) and Chain-of-Custody (COC) during all stages of production, particularly in closed versus open systems. This article serves as a detailed guide to navigating these critical validation…

Continue Reading COI/COC in Closed vs Open Steps

COI/COC Documentation Architecture

COI/COC Documentation Architecture Introduction to Chain-of-Identity and Chain-of-Custody Documentation The pharmaceutical industry, especially in the context of biologics and advanced therapy medicinal products (ATMPs), requires strict adherence to regulatory guidelines governing cold chain management, viral clearance validation, and potential contamination controls. The Chain of Identity (COI) and Chain of Custody (COC) are integral concepts that ensure the traceability and safety…

Continue Reading COI/COC Documentation Architecture

Risk Assessments for COI/COC Breaks

Risk Assessments for COI/COC Breaks Risk Assessments for COI/COC Breaks: A Comprehensive Guide In the realm of biologics and advanced therapy medicinal products (ATMP), the integrity of chain-of-identity (COI) and chain-of-custody (COC) is paramount. Compliance with regulatory expectations necessitates a robust approach to risk assessment, especially concerning viral clearance and control measures. This guide demystifies the multifaceted process of conducting…

Continue Reading Risk Assessments for COI/COC Breaks

COI/COC in Clinical vs Commercial Settings

COI/COC in Clinical vs Commercial Settings Understanding Chain-of-Identity and Chain-of-Custody in Clinical vs Commercial Settings The concepts of Chain of Identity (COI) and Chain of Custody (COC) serve as the foundation for ensuring the integrity of biologics, particularly in the context of Advanced Therapy Medicinal Products (ATMP) and viral safety validation. This article provides a comprehensive guide for pharma professionals…

Continue Reading COI/COC in Clinical vs Commercial Settings

Bridging COI/COC Across Countries/Regulators

Bridging COI/COC Across Countries/Regulators In the evolving landscape of biotechnology and pharmaceuticals, ensuring the integrity and safety of biologics through rigorous validation processes is paramount. This guide focuses on bridging the gaps in Chain of Identity (COI) and Chain of Custody (COC) across different regulatory environments, specifically guided by frameworks and expectations from authorities such as the US FDA, EMA,…

Continue Reading Bridging COI/COC Across Countries/Regulators

COI/COC KPIs: Completeness, On-Time, Error Rate

COI/COC KPIs: Completeness, On-Time, Error Rate COI/COC KPIs: Completeness, On-Time, Error Rate The pharmaceutical industry, especially in the realms of biologics and advanced therapy medicinal products (ATMP), demands stringent validation processes to ensure quality and compliance. Understanding key performance indicators (KPIs) for chain-of-identity (COI) and chain-of-custody (COC) is critical for achieving regulatory adherence as per guidelines set forth by agencies…

Continue Reading COI/COC KPIs: Completeness, On-Time, Error Rate